SMT202100302T1 - Composti di amminopurina sostituiti, loro composizioni e metodi di trattamento con gli stessi - Google Patents
Composti di amminopurina sostituiti, loro composizioni e metodi di trattamento con gli stessiInfo
- Publication number
- SMT202100302T1 SMT202100302T1 SM20210302T SMT202100302T SMT202100302T1 SM T202100302 T1 SMT202100302 T1 SM T202100302T1 SM 20210302 T SM20210302 T SM 20210302T SM T202100302 T SMT202100302 T SM T202100302T SM T202100302 T1 SMT202100302 T1 SM T202100302T1
- Authority
- SM
- San Marino
- Prior art keywords
- compositions
- methods
- aminopurine compounds
- treatment therewith
- substituted aminopurine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| EP15848476.6A EP3204386B1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100302T1 true SMT202100302T1 (it) | 2021-07-12 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210302T SMT202100302T1 (it) | 2014-10-06 | 2015-10-05 | Composti di amminopurina sostituiti, loro composizioni e metodi di trattamento con gli stessi |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (enExample) |
| EP (2) | EP3822274B1 (enExample) |
| JP (4) | JP6884701B2 (enExample) |
| KR (2) | KR20230035424A (enExample) |
| CN (2) | CN113248506A (enExample) |
| AR (2) | AR102171A1 (enExample) |
| AU (2) | AU2015328414B2 (enExample) |
| CA (1) | CA2963639C (enExample) |
| CL (1) | CL2017000820A1 (enExample) |
| CO (1) | CO2017003838A2 (enExample) |
| CY (1) | CY1124173T1 (enExample) |
| DK (1) | DK3204386T3 (enExample) |
| EA (1) | EA201790779A1 (enExample) |
| EC (1) | ECSP17026210A (enExample) |
| ES (2) | ES2980464T3 (enExample) |
| HR (1) | HRP20210656T1 (enExample) |
| HU (1) | HUE054694T2 (enExample) |
| IL (2) | IL251566B (enExample) |
| LT (1) | LT3204386T (enExample) |
| MX (2) | MX388321B (enExample) |
| PL (1) | PL3204386T3 (enExample) |
| PT (1) | PT3204386T (enExample) |
| RS (1) | RS61884B1 (enExample) |
| SG (2) | SG10202009598VA (enExample) |
| SI (1) | SI3204386T1 (enExample) |
| SM (1) | SMT202100302T1 (enExample) |
| TW (1) | TW201629063A (enExample) |
| WO (1) | WO2016057370A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054694T2 (hu) * | 2014-10-06 | 2021-09-28 | Signal Pharm Llc | Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei |
| JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ，エルエルシー | 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 |
| US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| KR102696304B1 (ko) | 2015-03-18 | 2024-08-16 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf의 억제제로서 유용한 헤테로시클릭 화합물 |
| SG11201707469WA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Substituted tricyclic heterocyclic compounds |
| WO2016149437A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
| WO2017019487A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| KR102679517B1 (ko) | 2015-08-03 | 2024-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf 알파의 조정제로서 유용한 시클릭 화합물 |
| CN109819649B (zh) * | 2016-04-01 | 2023-02-28 | 西格诺药品有限公司 | 氨基嘌呤化合物的固体形式及其使用方法 |
| SG10202009589UA (en) | 2016-04-01 | 2020-10-29 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| AR108665A1 (es) | 2016-06-02 | 2018-09-12 | Celgene Corp | Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania |
| WO2017210399A1 (en) * | 2016-06-02 | 2017-12-07 | Celgene Corporation | Animal and human anti-malarial agents |
| CA3078368A1 (en) | 2017-10-04 | 2019-04-11 | Celgene Corporation | Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| WO2019070827A1 (en) | 2017-10-04 | 2019-04-11 | Celgene Corporation | PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| JP2009516707A (ja) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| ES2567051T3 (es) | 2006-10-27 | 2016-04-19 | Signal Pharmaceuticals, Llc | Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos |
| PT2279731E (pt) | 2008-04-23 | 2013-08-30 | Farmasierra Mfg S L | Composição farmacêutica melhorada contendo ibuprofeno e codeína |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| HUE054694T2 (hu) | 2014-10-06 | 2021-09-28 | Signal Pharm Llc | Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei |
| CN109819649B (zh) | 2016-04-01 | 2023-02-28 | 西格诺药品有限公司 | 氨基嘌呤化合物的固体形式及其使用方法 |
-
2015
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
| IL262007A (en) | Modified aminopurine compounds, their compositions and methods of treatment using them | |
| IL266560A (en) | Endophytes, related preparations and methods of using them | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| GB201701673D0 (en) | Methods of well treatment | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
| EP3207048A4 (en) | Compositions and methods of treating muscular dystrophy | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| PL3102555T3 (pl) | Kompozycje związków i ich zastosowania | |
| ZA201706257B (en) | Treatment of wood | |
| SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
| PL2998311T3 (pl) | Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie | |
| GB201416832D0 (en) | Methods of treatment | |
| EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| ZA201608775B (en) | Hair treatment composition | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201418272D0 (en) | Composition & methods of treatment | |
| GB201418268D0 (en) | Composition & methods of treatment |